Study of serum adiponectin and resistin in patients with obstructive sleep apnea

• Main Authors: Mohamed H Zidan, Heba S Gharraf, Mona W Ayad, Heba S Gaid
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2019-01-01
• Series: Egyptian Journal of Chest Disease and Tuberculosis
• Subjects: adiponectin; metabolic disease; obstructive sleep apnea; resistin
• Online Access: http://www.ejcdt.eg.net/article.asp?issn=0422-7638;year=2019;volume=68;issue=3;spage=303;epage=309;aulast=Zidan

Background The syndrome of obstructive sleep apnea (OSA) is a very common disorder with several important complications and is still underdiagnosed. Obesity is considered to be a chronic disease rather than a lifestyle disorder. Adipose tissue secretory function is disturbed by chronic intermitted hypoxia occurring in OSA. The aim of this study was to study the level of serum adiponectin and resistin in patients with OSA and we tried to assess their association to different parameters of sleep disordered breathing (SDB) as well as concomitant comorbidities in each patient. Patients and methods This study contained two groups: Patients of group 1 included 30 newly diagnosed OSA patients and controls (group 2) included 15 healthy volunteers. All patients were subjected to overnight polysomnography, routine laboratory investigations, spirometry, and fasting serum adiponectin and resistin. Results Patients had statistically significant lower serum adiponectin level than controls while serum resistin levels were statistically significant higher in patients than controls. Moreover, serum adiponectin levels were significantly decreased with increased severity of OSA while serum resistin levels were increased significantly with increased severity of OSA. Moreover, there was a statistically significant decrease in serum adiponectin levels in the patients’ group with increasing number of comorbidities existing in every patient. There was a statistically significant increase in serum resistin levels in the patients’ group with increasing number of comorbidities existing in every patient. Conclusion This highlights the possible relationship of these hormones with the metabolic complications seen in OSA patients.